|
Teva Pharmaceuticals, a US affiliate of Teva Pharmaceutical Industries Ltd, announced new data that highlight the comprehensive tardive dyskinesia (TD) symptom improvement from treatment with its drugs Austedo and Austedo XR (extended release). The new findings, drawn from three separate studies, were presented at Psych Congress Elevate, held June 3 to 6, 2026, in Las Vegas, Nevada.
“The data presented at Psych Congress Elevate represent Teva’s pursuit to better understand the full human experience of tardive dyskinesia,” said Eric Hughes, MD, PhD, executive vice president, global R&D and chief medical officer at Teva. "We are dedicated to not only advancing science but also striving to close critical gaps in diagnosis and clinical management of tardive dyskinesia. By generating robust evidence for a broader range of patients, including those with mild TD, and providing insights that guide optimal long-term treatment strategies, we are working to deliver innovations that make a meaningful difference in the day-to-day lives of those living with this condition.”
The new findings from Teva’s latest research include new real-world insights from the IMPACT-TD registry, the largest real-world study of TD, evaluated patients with mild symptoms who were starting Austedo or Austedo XR treatment. At three months, all participants showed reductions in their Abnormal Involuntary Movement Scale (AIMS) score while maintaining their psychiatric stability; and participants with a clinically meaningful baseline burden in areas such as activities of daily living, psychosocial functioning, speech and communication reported improvement in these domains due to the reduction of TD movements.
An analysis from the 3-year RIM-TD open-label study found that an increasing percentage of patients responded to treatment over the course of the study. While >50% showed AIMS improvement within 15 weeks, an additional 23% saw improvement after week 15. This underscores the possibility of increasing improvement when patients stay on treatment.
A study focused on caregiver education found that providing TD-specific educational content developed in collaboration with patient advocacy groups via online platforms prompted crucial conversations with healthcare professionals. Within six months, 53% of care recipients at risk of TD discussed TD with a provider, and 34% received a TD diagnosis, highlighting an effective strategy to improve disease recognition.
"These findings are significant because they add to the real-world evidence supporting treatment benefit for patients with mild tardive dyskinesia," said Richard Jackson, MD, Assistant Clinical Adjunct Professor at the University of Michigan School of Medicine’s Department of Psychiatry and IMPACT-TD principal investigator. "In clinical practice, we know that even so-called 'mild' involuntary movements can have a profound, multidimensional impact on a person's quality of life. These data give clinicians greater confidence to identify and treat TD early, offering the potential to improve outcomes for patients who might have previously been overlooked."
TD is a highly debilitating, chronic movement disorder that affects one in four people who take certain mental health treatments and is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, and/or other body parts, which may be disruptive and negatively impact individuals. Austedo and Austedo XR are the first vesicular monoamine transporter 2 (VMAT2) inhibitors approved by the US Food and Drug Administration in adults for the treatment of tardive dyskinesia and for the treatment of chorea associated with Huntington’s disease. Safety and effectiveness in paediatric patients have not been established. The drug is indicated in adults for the treatment of chorea associated with Huntington’s disease and for the treatment of TD.
|